JNJ Jan 2025 165.000 call
| Previous Close | 18.13 |
| Open | 17.79 |
| Bid | 18.15 |
| Ask | 19.40 |
| Strike | 165.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 17.25 - 18.20 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 250 |
- Yahoo Finance
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
- Reuters
COLUMN-3M foes act fast to capitalize on J&J’s talc bankruptcy defeat
When a U.S. appeals court ruled on Monday that Johnson & Johnson can’t use the U.S. bankruptcy system to offload vast litigation exposure from product liability claims, the people who reacted most quickly were undoubtedly J&J investors. Within hours of the 3rd U.S. Circuit Court of Appeals decision, investors drove J&J’s share price down by nearly 4% -- its biggest one-day decline in years. But another, albeit much smaller, group of people was also roiled by Monday’s ruling from the 3rd Circuit: appellate lawyers who were finishing up friend-of-the-court briefs due on Wednesday in a 7th Circuit appeal by 3M Co that presents issues similar to those in the J&J case.
- Business Wire
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
NEW BRUNSWICK, N.J., February 02, 2023--Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).
